Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Pipeline Has Six NMEs That Could Launch By 2011, CEO Taurel Says

Executive Summary

Lilly plans to launch an average of two products per year beginning in 2011 and three per year beginning in 2014, CEO Sidney Taurel told analysts Dec. 6 in New York

You may also be interested in...



Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

Lilly Leadership Falls To Lechleiter In ’08 As Taurel Resigns As CEO

The appointment of Lilly President and Chief Operating Officer John Lechleiter to CEO should be a smooth transition in early 2008 when longtime chief exec Sidney Taurel retires

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel